Discover
FATE
Fate Therapeutics, Inc.
3.02
2 x 2.22
2 x 3.40
bid
ask
+
0.32
11.85%
2 @ 05:55 AM
2.97 -0.05 (1.59%)
| Ytd | 208.16% | |
| 1y | 164.91% |
2.64
day range
3.11
0.91
52 week range
3.11
| Open | 2.65 | Prev Close | 2.70 | Low | 2.64 | High | 3.11 | Mkt Cap | 352.01M |
| Vol | 5.86M | Avg Vol | 3.75M | EPS | -1.09 | P/E | N/A | Forward P/E | -0.99 |
| Beta | 1.88 | Short Ratio | 3.10 | Inst. Own | 102.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.02 | 200-d Avg | 1.40 | 1yr Est | 6.31 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.42 | -0.4 | 0.02 | 4.76% |
| 2024-08-13 | 2024-06 | -0.47 | -0.33 | 0.14 | 29.79% |
| 2024-05-09 | 2024-03 | -0.47 | -0.47 | N/A | N/A |
| 2024-02-26 | 2023-12 | -0.57 | -0.45 | 0.12 | 21.05% |
| 2023-11-08 | 2023-09 | -0.59 | -0.46 | 0.13 | 22.03% |
| 2023-08-08 | 2023-06 | -0.58 | -0.54 | 0.04 | 6.90% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-19 | Needham | Upgrade | Hold | |
| 2024-11-13 | Needham | Upgrade | Hold | |
| 2024-08-22 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-08-14 | Needham | Upgrade | Hold | |
| 2024-06-17 | Piper Sandler | Upgrade | Neutral | Overweight |
| 2024-05-16 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-04-17 | CHU YU-WAYE | Officer | 140.68K | Sale |
| 2024-03-03 | DULAC EDWARD J III | Chief Financial Officer | 101.48K | Sale |
| 2023-01-18 | MENDLEIN JOHN D | Director | 311.23K | Conversion of Exercise of derivative security |
| 2023-01-09 | PLAVSIC MARK | Chief Technology Officer | 123.71K | Sale |
| 2023-07-04 | POWL BRIAN T | Officer | 41.15K | Sale |
| 2024-12-11 | REDMILE GROUP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Redmile Group, LLC | 13.17M | 21.86M | 11.56% |
| 2024-09-29 | Blackrock Inc. | 10.47M | 17.39M | 9.20% |
| 2024-09-29 | Vanguard Group Inc | 10.40M | 17.27M | 9.13% |
| 2024-09-29 | Deep Track Capital, Lp | 5.57M | 9.25M | 4.89% |
| 2024-09-29 | State Street Corporation | 5.25M | 8.72M | 4.61% |
| 2024-09-29 | Boxer Capital, LLC | 4.96M | 8.24M | 4.36% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 3.05M | 5.06M | 2.68% |
| 2024-10-30 | iShares Russell 2000 ETF | 2.58M | 4.29M | 2.27% |
| 2024-09-29 | Vanguard Strategic Equity Fund | 2.54M | 4.22M | 2.23% |
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.46M | 4.09M | 2.16% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.41M | 2.34M | 1.24% |
| 2024-07-30 | Vanguard Explorer Fund, Inc. | 1.27M | 2.11M | 1.11% |